Ludovica Ceci
Curriculum Vitae

Place: Roma
Date: 27/05/2025

Part I – General Information

Full Name	Ludovica Ceci
Citizenship	Italiana
Permanent Address	
Spoken Languages	Italiana (madrelingua), Inglese (C1)

Part II – Education

II-A -Qualifications

Type	Year	Institution	Notes (Degree, Experience,…)
Undergraduate Study	2010/2011	Liceo Scientifico Majorana	Liceo Scientifico (83/100)
University graduation	2014	University of Camerino	Biologia della Nutrizione, Laurea Triennale. (Titolo Tesi: "Analisi Morfometrica di *Corydalis Densiflora* (*Papaveracea*e)").
Post-graduate studies	2016	University of Camerino	Biological sciences, curriculum Molecular diagnostics and biotechnology. Laurea Magistrale. (Titolo Tesi: "Effects of probiotics and *Korean ginseng* administration on the oxidative status of Alzheimer's disease murine model" in clinical and molecular diagnostics")
PhD	2025	University of Rome Sapienza	Epato-Gastroenterologia Sperimentale e clinica. (Titolo tesi: *Il ritmo circadiano nei modelli murini di colestasi*)

II-B -Training course

Year	Institution	Notes
18/05/2018	Biomedical Responsible Conduct of Research	Basic Course (ID 38337)
23/12/2021	Human Research - Biomedical Researcher	Stage 1 and stage 2 (ID 40254)
23/12/2021	SoD - Working with the IACUC - Investigators, Staff and Students	Lab Animal Research(ID 47546)

07/06/2018	SoM - Reducing Pain and Distress in Laboratory Mice and Rats	Lab Animal Research(ID 49449)
15/07/2021	SoM - Working with Mice in Research Settings - SoM - Working with Mice in Research	Lab Animal Research (ID 49452)
15/06/2021	SoM - Working with Rats in Research Settings - SoM - Working with Rats in Research Settings	Lab Animal Research (ID 49453)
23/12/2021	SoS - Working with the IACUC – Investigators, Staff and Students - SoS – Working with the IACUC – Investigators, Staff and Students	Basic Course (ID 104259)
15/01/2020	Good Laboratory Practice (GLP)	GLP (ID 112619)
23/12/2021	Working with the IACUC - Investigators, Staff and Students	Basic Course (ID 112928)
13/01/2020	NIH Recombinant DNA Guidelines	IBC/Biosafety (ID 114056)
23/12/2021	IUNW - Lab Animal Research - IUNW - Working with the IACUC - Investigators, Staff and Students	Basic (ID 170092)
16/02/2019	IUEHS Safety & Health for Animal Users Training	Basic (ID 167759)
09/07/2022	Bloodborne Pathogens Training for IBC Researchers	Basic Course (ID 185927)
15/01/2020	IUEHS Biosafety Training	Basic Course (ID 186470)

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position
01/10/2013	31/03/2014.	University of Ulster	Studente-Programma Erasmus
01/10/2011	26/09/2014.	Università di Camerino	Studente
11/10/2014	15/12/2016	Università di Camerino	Studente
01/11/2021	31/10/2024	Università La Sapienza di Roma	PhD
01/01/2019	31/10/2021	Indiana University, Medical School	Assistente di Ricerca
12/01/2018	01/01/2019	Texas A&M Health Science Center	Assistente di Ricerca

Part IV – Teaching experience

Start date	End date	Institution	Lecture/Course
10/02/2025	31/03/2026	Link Campus University	Anatomia Umana/ Laurea Magistrale a Ciclo Unico LM-13, Farmacia
02/12/2024	31/03/2026	Link Campus University	Anatomia Umana/ Infermieristica (L/SNT1, Fondamenti Morfologici e Funzionali dell'Organismo)

2021	Presente	Sapienza Università di Roma	Attività didattica integrativa nel Corso di laurea magistrale a ciclo unico in Medicina e Chirurgia A.

Part V - Society memberships, Awards and Honors

Year	Title
2022-2024	Società Italiana d'Istochimica
2023- 2024	Società Italiana d'Anatomia e Istologia
2018-2023	American Association for the study of liver diseases (AALSD) membership
2022	American Society for Investigative Pathology (ASIP) membership

Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Grant value
2024	Profiling of cholangiocarcinoma with a spatial multi-omics approach for the definition of histological subtypes	Progetti di ricerca medi, Sapienza Università di Roma. PI: Prof. Eugenio Gaudio	9 872,96 euro
2023	Ruolo del ritmo circadiano e del PER1 nello sviluppo di colangicoarcinoma da colangite sclerosante primitiva (CSP)	Progetti di ricerca Sapienza, Università di Roma, Avvio alla ricerca. PI: Dott.ssa Ludovica Ceci	1 200 euro
2022	Ruolo della melatonina e del ritmo circadiano nella regolazione della crescita dell'epitelio biliare	Progetti di ricerca medi, Sapienza Università di Roma. PI: Prof.ssa Romina Mancinelli	10 000 euro

Part VII – Research Activities

Keywords	Brief Description
Melatonina, Recettori della melatonina, ritmo circadiano periferico, albero biliare, colangiociti	**Ruolo dell'asse melatonina- geni CLOCK nelle patologie colestatiche** Il ruolo del ritmo circadiano periferico (CLOCK, PER1, ARNTL, CRY1) è stato studiato nei colangiociti di modelli murini colestatici (Mdr2-/-, e topi sottoposti a legatura del dotto biliare (BDL)), ed in colangiociti isolati da pazienti con colangite sclerosante primitiva (CSP) dopo il trattamento con la melatonina. Inoltre, studi istomorfologici e immunoistochimici ci hanno permesso di osservare come i modelli murini colestatici utilizzati presentano infiammazione intestinale rispetto ai gruppi controllo che potrebbe suggerire un collegamento tra l'asse gut–liver e i disordini del ritmo circadiano (CRD), come già correlati con fegato grasso e gastroenterite cronica.
Neuropeptidi, patologie epatiche, albero biliare, cholangiociti, cellule stellate, senescenza cellulare	**Il ruolo dei neuropeptidi nelle patologie del fegato** α-CGRP, Sostanza P, secretina e serotonina sono stati studiati come neuro-ormoni e neuropeptidi coinvolti nell'asse brain-liver. In particolare, attraverso studi istomorfologici e immmunoistochimici abbiamo osservato come il silenziamento di questi neuropeptidi/neuro-ormoni possa influenzare il fenotipo epatico nei modelli murini colestatici (Mdr2-/- e BDL) e metabolici (topi trattati con High fat diet (HFD)). Inoltre, abbiamo

	notato che questi fattori possono influenzare il processo di senescenza dei colangiociti e delle cellule stellate (HSCs) in modo differente nel corso di patologie colestatiche.
Morte cellulare, ferroptosis, infiammazione intestinale, TNBS, malattie neurodegenerative	**Gut-liver-brain axis**
	L'espressione di α-sinucleina (α-Syn) e altri neuropeptidi, come vasoactive intestinal peptide (VIP), tyrosine hydroxylase (TH), choline acetyltransferase (ChAT) e i loro rispettivi recettori è stata studiata nel colon infiammato di topi trattati con TNBS (acido 2,4,6-trinitrobenzene sulfonico, modello murino di colite) attraverso tecniche istomorfologiche e immunoistochimiche, dimostrando che alcuni dei neuropeptidi aumenta mentre altri diminuiscono in corso d'infiammazione intestinale, supportando un ruolo fondamentale del sistema nervoso enterico (ENS) nel trasmettere segnali al sistema nervoso centrale (CNS) attraverso il fegato. Inoltre, dati mostrano che vi è uno stretto legame tra l'infiammazione intestinale e α-syn, la quale formando aggregati nelle cellule infiammatorie durante una colite può trasferirsi lungo l'asse gut–liver- brain. In questo asse è di fondamentale importanza anche capire il ruolo della ferroptosi, una tipologia di morte cellulare programmata dipendente dal ferro, che ha nel fegato il suo metabolismo e che potrebbe fornire indicazioni su possibili meccanismi di connessione tra i vari organi dell'asse.

VII B – National and International Conferences

Role	Year	Notes
Presentazione	2024	77° Congresso della Società Italiana di Anatomia e Istologia. Genova.
	2023	76° Congresso Nazionale Società Italiana di Anatomia e Istologia. Modena.
	2023	XXXIX Congresso Nazionale della Società Italiana di Istochimica, Vulcano.
	2023	European Student Symposium on Anatomical Research (online).
	2022	16th Congresso Internazionale della Società Italiana di Istochimica, Praga (**Young Histochemist Award**).
	2022	Experimental Biology (EB), Philadelphia (USA).
	2021	4th Scientific Program Committee of the SCBA-Hepatology and Chinese-American Liver Society (CALS), Annual Symposium (online).
Poster con distinzione	2020	Digestive Disease Week meeting, Chicago (USA).
	2020	AASLD liver meeting Digital Experience (online).
Poster	2020	Digestive Disease Week meeting, San Diego (USA).
Poster con distinzione	2019	Presented at AASLD liver meeting (2019, November). Boston (USA).
Poster	2018	AASLD liver meeting, San Francisco (USA):

Part VIII – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	33	Scopus	2019	2025
Books [scientific]	1	Scopus	2019	2025

Total Impact factor	273.078
Total Citations	582
Average Citations per Product	17.64
Hirsch (H) index	15
Normalized H index*	3

*****H index divided by the academic seniority.

Part IX– Selected Publications

Publications	Citations	IF (years)
1- Wan Y*, **L Ceci***, N Wu, T Zhou, L Chen, J Venter, H Francis, F Bernuzzi, P Invernizzi, K Kyritsi P Baker, Q Huang, C Wu, A Sybenga, G Alpini, F Meng, and S Glaser. *Knockout of α-calcitonin gene-related peptide attenuates cholestatic liver injury by differentially regulating cellular senescence of hepatic stellate cells and cholangiocytes.* **Lab Invest.** 2019 Jan 30. doi: 10.1038/s41374-018-0178-5 * share the first autorship	17	4.197 (2019)
2- **L Ceci,** H Francis, T Zhou, T Giang, Z Yang, F Meng, N Wu, L Kennedy, K Kyritsi, V Meadows, C Wu, S Liangpunsakul, A Franchitto, A Sybenga, B Ekser, R Mancinelli, P Onori, E Gaudio, S Glaser, and G Alpini. (2020). *Knockout of the tachykinin receptor 1 in the Mdr2-/- mouse model of primary sclerosing cholangitis reduces biliary damage and liver fibrosis.* **The American Journal of Pathology**. 2020 Nov;190(11):2251–2266. doi:10.1016/j.ajpath.2020.07.007	12	3.491 (2020)
3- Wu N, Baiocchi L, Zhou T, Kennedy L, **Ceci L**, Meng F, Sato K, Wu C, Ekser B, Kyritsi K, Kundu Alpini G. *The Functional Role of the Secretin/Secretin Receptor Signaling During Cholestatic Liver Injury.* **Hepatology**. 2020 Aug 1. doi: 10.1002/hep.31484.	18	17.425 (2020)
4- Kyritsi K, Chen L, O'Brien A, Francis H, Hein TW, Venter J, Wu N, **Ceci L**, Zhou T, Zawieja D, Gashev AA, Meng F, Invernizzi P, Fabris L, Wu C, Skill NJ, Saxena R, Liangpunsakul S, Alpini G, Glaser SS. *Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase-A/5-Hydroxytryptamine/5-Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.* **Hepatology**. 2020 Mar;71(3):990-1008. doi: 10.1002/hep.30880.	26	17.425 (2020)
5- Chen L, Wu N, Kennedy L, Francis H, **Ceci L**, Zhou T, Samala N, Kyritsi K, Wu C, Sybenga A, Ekser B, Dar W, Atkins C, Meadows V, Glaser S, Alpini G. *Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes.* **Hepatology**.2021 Oct;74(4):1845-1863. doi: 10.1002/hep.31871	22	17.298 (2021)
6- Kennedy L, Meadows V, Sybenga A, Demieville J, Chen L, Hargrove L, Ekser B, Dar W, **Ceci L**, Kundu D, Kyritsi K, Pham L, Zhou T, Glaser S, Meng F, Alpini G, Francis H. *Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and*	41	17.298 (2021)

Microvesicular Steatosis in Mice Fed a Western Diet. **Hepatology**. 2021 Jul;74(1):164-182. doi: 10.1002/hep.31713.		
7- N Wu, G Carpino, **L Ceci**, L Baiocchi, H Francis, L Kennedy, T Zhou, L Chen, K Sato, K Kyritsi, V Meadows, B Ekser, A Franchitto, R Mancinelli, P Onori, E Gaudio, S Glaser, G Alpini. *Melatonin receptor 1A, but not 1B, knockout decreases biliary damage and liver fibrosis during* cholestatic liver injury. **Hepatology,** 2022 Apr;75(4):797-813. doi: 10.1002/hep.32233.	22	14.0 (2022)
8- **Ceci L**, Zhou T, Lenci I, Meadows V, Kennedy L, Li P, Ekser B, Milana M, Zhang W, Wu C, Sato K, Chakraborty S, Glaser SS, Francis H, Alpini G, Baiocchi L. *Molecular Mechanisms Linking Risk Factors to Cholangiocarcinoma Development.* **Cancers (Basel)**. 2022 Mar 11;14(6):1442. Doi:10.3390/cancers14061442.	11	5.2 (2022)
9- **L Ceci**, L Chen, L Baiocchi, N Wu, L Kennedy, G Carpino, K Kyritsi, T Zhou, T Owen, D Kundu, A Sybenga, A Isidan, B Ekser, A Franchitto, P Onori, E Gaudio, R Mancinelli, H Francis, G Alpini, S Glaser. *Prolonged administration of melatonin ameliorates liver phenotypes in cholestatic murine model.* **Cellular and Molecular Gastroenterology and Hepatology**, 2022;14(4):877-904. DOI: 10.1016/j.jcmgh.2022.07.007	7	7.2 (2022)
10- Kundu D, Kennedy L, Zhou T, Ekser B, Meadows V, Sybenga A, Kyritsi K, Chen L, **Ceci L**, Wu N, Wu C, Glaser S, Carpino G, Onori P, Gaudio E, Alpini G, Francis H. *p16 INK4A drives nonalcoholic fatty liver disease phenotypes in high fat diet fed mice through biliary E2F1/FOXO1/IGF-1 signaling*. **Hepatology**. 2023 Jul 1;78(1):243-257. Doi:10.1097/HEP.0000000000000307.	13	13 (2023)
11- L Kennedy, G Carpino, T Owen, **L Ceci**, D Kundu, V Meadows, K Kyritsi, A Franchitto, P Onori, A Isidan, W Zhang, B Ekser, D Alvaro, E Gaudio, M Er Gershwin, H Francis, S Glaser, G Alpini. *Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes.* **J Hepato**. Jan 2023, 17;S0168-8278(22)02999-3. doi: 10.1016/j.jhep.2022.07.034.	21	26.8 (2023)
12- N Wu, T Zhou, G Carpino, L Baiocchi, K Kyritsi, L Kennedy, **L Ceci**, L Chen, C Wu, D Kundu, N Barupala, A Franchitto, P Onori, B Ekser, E Gaudio, H Francis, S Glaser, G Alpini. *Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2 -/- mice*. **Hepatology**. 2023 Feb 20. doi: 10.1097/HEP.0000000000000310.	5	13.0 (2023)

Complete list of publications in international, peer-reviewed journals

Link: https://pubmed.ncbi.nlm.nih.gov/?term=ceci+ludovica&sort=date

Conference abstracts

1. **L Ceci,** R Mancinelli, S Leone, A Franchitto, L Pannarale, P Onori, E Gaudio, "*Role of period circadian protein 1 (PER1) in the determination of gender differences during cholestatic diseases".* 77° Congresso della Società Italiana di Anatomia e Istologia. Genova, 12-14 settembre 2024 [Presenter]
2. **L Ceci,** A Franchitto, S Leone, L Pannarale, P Onori: "*Interactions between melatonin and estrogen may regulate cholestatic liver phenotype in female Mdr2-/- mice*". 76° Congresso Nazionale Società Italiana di Anatomia e Istologia. MODENA, 11 – 13 SETTEMBRE 2023. [Presenter]

3. **L Ceci,** R Mancinelli, A Franchitto, L Pannarale, P Onori, E Gaudio. LONG-TERM EFFECTS OF MELATONIN ON ESTROGEN SIGNALING IN CHOLANGIOCYTES DURING PSC. XXXIX Congresso Nazionale della Società Ita,liana di Istochimica (14-16 june), 2023. Vulcano [Presenter]
4. **L Ceci,** Sapienza, Università di Roma, The effects of melatonin/MT1 axis in cholestasis. Presented at European Student Symposium on Anatomical Research 2023 (May, 10-11). Online. [Presenter]
5. **L Ceci,** L Kennedy, G Carpino, B Ekser, S Glaser, A Franchitto, P Onori, H Francis, G Alpini, R Mancinelli, E Gaudio Sapienza, Università di Roma. Long term effects of melatonin on cholestatic murine model. 16th ICHC (28-31 August), 2022. Prague [Presenter]
6. **L Ceci,** N Wu, G Carpino, L Chen, T Zhou, L Kennedy, K Kyritsi, H Francis, A Franchitto, P Onori, E Gaudio, S Glaser, G Alpini. "Suppression of MT1 and Melatonin Treatment Improves Liver Phenotypes in Mdr2 mice". EB (2-5 April) 2022. [Presenter]
7. **L Ceci,** Indiana University School of Medicine "Prolonged administration of melatonin improved primary sclerosis cholangitis (PSC) phenotypes through clock genes/miR200b/MASPIN/GST signaling pathway". 4th Scientific Program Committee of the SCBA-Hepatology and Chinese-American Liver Society (CALS), Annual Symposium (October 29-30) 2021. [Presenter].
8. **L Ceci,** N Wu, H Francis, L Chen, T Zhou, L Kennedy, K Kyritsi, K Grumbles, J Rivosecchi-Fulton, V Meadows, C Wu, D Kundu, F Meng, A Franchitto, E Gaudio, P Onori, R Mancinelli, G Alpini, and S Glaser. *Prolonged administration of melatonin to the Mdr2 mouse model of Primary Sclerosis Cholangitis (PSC) decrease biliary Senescence and Liver fibrosis through restoration of the Circadian Rhythm*. Presented at Digestive Disease Week meeting (2020, May). Chicago [Poster with distinction]
9. **L Ceci,** L Kennedy, H Francis, L. Chen, N Wu, T Zhou, F Meng, D Kundu, K Kyritsi, V Meadows, B Ekser, A Franchitto, K Grumbles, P Onori, R A Mancinelli, E Gaudio, S Glaser and G Alpini. *Long-Term melatonin treatment of the Mdr2-/- mouse model of Primary sclerosing cholangitis (PSC) reduces peribiliary inflammation and oxidative stress.* AASLD liver meeting Digital Experience (2020, November). [Poster with distinction]
10. **L Ceci,** Indiana University School of Medicine "*Prolonged administration of melatonin to the Mdr2 mouse model of primary sclerosis cholangitis (PSC) decreases inflammation and oxidative stress through the restoration of the circadian rhythm*."3rd Scientific Program of the SCBA-Hepatology and Chinese- American Liver Society (CALS), Annual Symposium (October 30-31) 2020. [Presenter].
11. **L Ceci,** N Wu, L Chen, A O'Brien, T Zhou, L Kennedy, K Kyritsi, E Gaudio, J Venter, F Meng, P Onori, H Francis, S Glaser, and G Alpini. Role of the AANAT/melatonin/MT1/MT2/Per-1 axis in the regulation of biliary damage and liver fibrosis in cholestatic mice. Gastroenterology, 156: S-1305, 2019. Presented at Digestive Disease Week meeting (2020, May). San Diego [Poster]
12. R Mancinelli, **L Ceci,** P Onori, A Franchitto, N Wu, D Alvaro, M Marzioni , Kennedy, H Francis, J Venter, T Zhou, S Liangpunsakul, F Meng, S Glaser, G Alpini, and E Gaudio. *Knock-out (KO) of α -calcitonin gene-related peptide (α-CGRP) reduces sodium taurocholate (TC)-induced biliary damage, ductular reaction (DR) and liver fibrosis*. Presented at AASLD liver meeting (2019, November). Boston [Poster with distinction].
13. **L Ceci,** N Wu, K Kyritsi, L Kennedy, T Zhou, J Venter, L Chen, H Francis, F Meng, G Alpini and S Glaser. *Knock-out of the Clock Gene, Period Circadian Protein 1 (PER1) Exacerbates Cholestatic-Induced Biliary Damage/Senescence and Liver Fibrosis Via Downregulation of Hepatic Melatonin Synthesis*. Presented at AASLD liver meeting (2018, November). San Francisco [Poster].
14. Y Wan, **L Ceci**, J Venter, T Giang, N Wu, K Kyritsi, L Chen, P Baker, H Francis, S Glaser, G Alpini and F Meng. *A-Calcitonin Gene-Related Peptide (α-CGRP) Increases Liver Fibrosis By Regulating Cellular Senescence and Activation of PKC/JNK Pathway in Bile Duct Ligated (BDL) Mice.* Presented at AASLD liver meeting (2018, November). San Francisco [Poster].
15. L Kennedy, L Chen, N Wu, **L Ceci**, V Meadows, B Ekser, S Liangpunsakul, S Glaser, H Francis, and G Alpini. *Combined ursodeoxycholic acid (UDCA) and secretin receptor antagonist (SEC 5-27)*

treatment decreases liver damage by coordinately decreasing both secretin (Sct) and FXR/FGF signaling in primary sclerosing cholangitis (PSC). Gastroenterology 158, S-1285, 2020

16. T Zhou, K Kyritsi, L Huang, N Wu, K McDaniel, Z Yang, K Sato, C Wu, **L Ceci**, L Chen, H Francis, S Glaser, S Liangpunsakul, G Alpini, and F Meng. *Promotion of M1 macrophage polarization and ductular reaction by microRNA-34a during cholestatic liver injury*. Gastroenterology: 158, S-1313, 2020
17. T Zhou, N Wu, L Chen, **L Ceci**, A O'Brien, T White, L Kennedy, C Wu, F Meng, H Francis, G Alpini, and S Glaser. *Melatonin modulates stimulator of interferon genes (STING) activation in the Mdr2-/- mouse model of primary sclerosing cholangitis (PSC*). Gastroenterology 158, S-1262, 2020.
18. L Chen, N Wu, S Glaser, **L Ceci**, L Kennedy, F Meng, V Meadows, D Kundu, G Alpini, and H Francis. *Treatment with melatonin or dark therapy decreases mast cell (MC) activation by downregulation of miR-200b dependent histamine (HA) signaling in mdr2-/- mice: a novel scenario for PSC management.* Gastroenterology 158: S-1266, 2020.
19. K Sato, K Kyritsi, H Francis, E Slevin, K Grumbles, L Kennedy, N Wu, L Chen, S Liangpunsakul, Z Yang, W Xu, **L Ceci**, S Glaser, G Alpini, and F Meng. *Cholangiocarcinoma cells secrete extracellular vesicles that contribute to cytokine expression and fibrogenesis during the tumor microenvironment development*. Gastroenterology: 158, S-1309, 2020.
20. N Wu, L Kennedy, T Zhou, K Kyritsi, L Chen, **L Ceci**, K Grumbles, H Francis, V Meadows, F Meng, B Ekser, A O'Brien, J Rivosecchi-Fulton, P Onori, E Gaudio, T White, S Glaser, and G Alpini. *Long-term administration of the secretin receptor antagonist, Sct 5-27, inhibits biliary senescence and liver fibrosis of primary sclerosing cholangitis (PSC) in the Mdr2-/- mouse model*. Gastroenterology 158: S-1277, 2020.
21. D Kundu, V Meadows, L Kennedy, **L Ceci**, K Kyritsi, L Chen, N Wu, K Cerritos, S Glaser, G Alpini, and H Francis. *Coordinated regulation of sensory innervation and mast cell activation contributes to biliary damage and hepatic fibrosis*. Gastroenterology 158: S-1310, 2020.
22. T Zhou, S Glaser, **L Ceci**, N Wu4, Z Yang, P Kusumanchi, W Xu, L Kennedy, S Liangpunsakul, H Francis, G Alpini, and F Meng. *Long noncoding RNA UC.338 regulates hepatic stellate cell activation in stem cell derived extracellular vesicles during alcoholic liver injury*. Hepatology 70, 893A-893A, 2019.
23. N Wu, T Zhou, L Kennedy, H Francis, F Meng, A O'Brien, **L Ceci**, P Kusumanchi, J Venter, Z Yang, E Gaudio, H Tsukamoto, B Gao, S Liangpunsakul, S Glaser, and G Alpini. *knockout of the secretin receptor (SR) reduces ductular reaction, biliary senescence and hepatic inflammation during alcohol-associated liver disease*. Hepatology 70, 842A-843A, 2019.
24. L Kennedy, H Francis, **L Ceci**, M Marzioni, P Invernizzi, V Meadows, R Mancinelli, P Onori, A Franchitto, E Gaudio, J Venter, F Meng, N Wu, D Alvaro, E Gershwin, S Liangpunsakul, G Alpini, and S Glaser. *Combined treatment with ursodeoxycholic acid (UDCA) and secretin (Sct) ameliorates liver injury in a mouse model of late stage primary biliary cholangitis (PBC*). Hepatology 70, 774A-774A, 2019.
25. K Sato, H Francis, L Kennedy, J Venter, P Kusumanchi, **L Ceci**, T Zhou, Z Yang, S Liangpunsakul, S Glaser, G Alpini, and F Meng. *Regulation of cholangiocyte proliferation and functions by extracellular vesicle injection in vivo*. Hepatology 70, 1113A, 2019.

I authorize the processing of personal data present in the CV pursuant to Legislative Decree 101/2018 and of the GDPR (EU Regulation 2016/679).

Rome, 27/05/2025
Ludovica Ceci

Il presente documento è composto di N=9 pagine. Ai sensi dell'art. 46 e 47 del DPR 445/2000, dichiaro che le informazioni inserite nel mio CV corrispondono a verità, essendo consapevole dell'eventuale applicazione dell'art.76 dello stesso articolo in caso di dichiarazione mendace.